Form 4: Karyopharm Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Stuart Poulton, EVP, Chief Development Officer of Karyopharm Therapeutics Inc., sold 189 shares of common stock on July 28, 2026 for $7.10 per share.
Summary
- Open-market sale: disposed of 189 Common Stock at $7.10 ($1,342) on July 28, 2026; holds 94,632 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,342 of stock on the open market.
Insider Transactions
Stuart Poulton — Officer (EVP, Chief Development Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Open-market sale | Common Stock | 189 | $7 | $1.3K | 94,632 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Open-market sale (189 shares) |
Keywords
insider transaction, Form 4, KPTI, Karyopharm Therapeutics Inc., bearish, Stuart Poulton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.